Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459356 | 0.86 | PPARA (0.49) | PPARACYP4F2CYP4A11ABCB11CYP1A2 | |
| SCHEMBL8621200 | 0.86 | PPARA (0.49) | PPARACYP4F2CYP4A11ABCB11CYP1A2 | |
| SCHEMBL10459075 | 0.84 | L3MBTL1 (0.59) | PPARACYP4F2CYP4A11POLB | |
| SCHEMBL8617055 | 0.82 | CYP4F2 (0.52) | PPARACYP4F2CYP4A11CYP3A4MEN1 | |
| SCHEMBL5727305 | 0.82 | PPARA (0.70) | PPARACYP4F2CYP4A11CYP1A2TSHR | |
| SCHEMBL10458719 | 0.81 | MAPT (0.60) | PPARACYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL10457436 | 0.81 | PPARA (0.49) | PPARACYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL10459179 | 0.81 | S1PR1 (0.46) | PPARACYP4F2CYP4A11 | |
| SCHEMBL8624692 | 0.81 | PPARA (0.45) | PPARACYP4F2CYP4A11 | |
| SCHEMBL21991986 | 0.81 | PPARA (0.60) | PPARACYP4F2CYP4A11ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | PPARA 1112/4885CYP4F2 253/4885CYP4A11 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.